金吾财讯 | 轩竹生物-B(02575)早盘股价上扬，曾一度升逾14%，最新报40.26元每股，涨幅8.26%，成交额2056万。消息面上，四环医药(00460)发布公告，公司旗下非全资附属公司轩竹生物科技股份有限公司的创新药安奈拉唑钠肠溶片(商品名：安久卫)用于治疗成人反流性食管炎的中国III期临床试验已顺利完成全部500名受试者入组。
据悉，安奈拉唑钠肠溶片于2023年6月获得中国国家药品监督管理局批准上市，用于患者治疗十二指肠溃疡。该药物具有创新的结构设计，并且合并用药的风险较小，是更适合中国人的质子泵抑制剂。此次III期临床研究于2025年7月全面展开，近期完成受试者入组，标志着本公司在创新药物研发方面取得了重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.